Participants Announced for Plenary Session of Drug Security Forum

The list of participants in the plenary session ‘Drug Security at the Heart of a Robust Healthcare System’ has been published on the official website of the Drug Security Forum, which will take place on 2 June during the opening day of the St. Petersburg International Economic Forum.

The session will be attended by Minister of Health of the Russian Federation Mikhail Murashko, World Health Organization Regional Director for Europe Hans Henri P. Kluge, United Nations Children’s Fund (UNICEF) Executive Director Henrietta Fore, Russian Federal Medical-Biological Agency Director Veronika Skvortsova, Head of the Subcommittee on the Circulation of Medicines and Development of the Pharmaceutical and Medical Industry of the Committee of the State Duma of the Federal Assembly of the Russian Federation on Health Protection Alexander Petrov, Head of the Federal Service for Surveillance in Healthcare (Roszdravnadzor) Alla Samoylova, European Federation of Pharmaceutical Industries and Associations Executive Director for International Affairs Koen Berden, UNICEF Regional Director for Europe and Central Asia Afshan Khan, and Chairman of the Board of the Eurasian Economic Commission Mikhail Myasnikovich. The meeting will be moderated by Doctor Channel Editor-in-Chief and Russia 24 Anchor Evelina Zakamskaya.

Global healthcare progresses in step with technological advances, and today there are entirely new algorithms for treating diseases. The COVID-19 pandemic showed that drug security is a top priority, both for the Russian and global economy. Factors such as drug quality certainty, as well as availability and long-term continuity of supply (even in emergency situations) are key to national security. The challenges presented by the pandemic have become a powerful stimulus for the development of new mechanisms to ensure drug availability, conduct rapid clinical studies, and develop and manufacture Russian vaccines. For citizens’ convenience, information technologies and monitoring of drug circulation are being expanded. For a country’s healthcare system and pharma industry to reach a new level of stable growth, ground-breaking technologies are needed. These technologies are also essential to join the international pharmaceutical market, where biomedical cell products are a new driver.

During the plenary session, experts will discuss what can be done to improve the supply of drugs for preventable diseases and avoid supply deficits, how regulation can be changed from acting as a barrier to a catalyst for innovation, what steps can be taken so that regulations are harmonized on the EAEU common pharmaceutical market, how to ensure national drug security, and how can Russian citizens be guaranteed continuous availability of high-quality, effective, leading-edge drugs?